Telix Pharmaceuticals (ASX:TLX) has taken another step in its push to bring novel radiopharmaceutical therapies to men with advanced prostate cancer, confirming that the first patient has now been treated in the randomised expansion phase of its pivotal ProstACT Global Phase 3 trial. …
Telix doses first patient in expanded Phase 3 prostate cancer trial
December 8, 2025 Australian Biotech
Latest Video
New Stories
-
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News -
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development
August 10, 2026 - - Latest News -
Australian company points to encouraging survival signal in mesothelioma CAR-T study
August 10, 2026 - - Australian Biotech -
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News